Navigation Links
Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/3/2008

WALTHAM, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI) announced today that Lewis H. Bender, Chief Executive Officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008, at 11:35 am EST. The conference will be held at the New York Palace Hotel in New York.

A live audio webcast of the presentation will be available on the Events section of the Interleukin Genetics website, http://www.ilgenetics.com/content/about-interleukin/events.jsp. A replay of the presentation will be available on the Company's website for 14 days following the presentation.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. The Company currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Interleukin-12 indicates survival prospects for melanoma patients
2. LaVoie Group Adds Interleukin Genetics to its Life Science Agency Roster
3. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
4. T cell immunity enhanced by timing of interleukin-7 therapy
5. Interleukin Genetics, Inc. Management to Present at Healthcare Conferences
6. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
7. DNA Direct and Iverson Genetics Announce Partnership to Provide Personalized Patient Reports for Warfarin Dosing Test Results
8. Genetics, Environment Shape Sexual Behavior
9. Homosexual behavior due to genetics and environmental factors
10. 2008 Gruber Genetics Prize awarded to Allan Spradling of Carnegie Institution
11. 6 Nobel Prize Winners at International Congress of Genetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... PITTSBURGH...Defibrillators are ... saves lives. However, if one isn’t accessible in certain locations, the risk of ... I came up with this idea," said an inventor from Ridgecrest, Calif. , ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... Safe Is Smart Scholarship Sweepstakes.,  , Molli C., a graduate student from Sonora, ... Educational Leadership and Administration at St. Thomas University in Miami, Florida, was selected ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... emergency rooms is celebrating the one year anniversary of its Houston-Fallbrook facility. ... said Dr. Otinwa, Facility Medical Director of First Choice Emergency Room Houston-Fallbrook. “It ...
(Date:9/22/2017)... Diego, CA (PRWEB) , ... September 22, 2017 ... ... offer groceries, wearable, and more products at customers’ doorstep. According to Smart Mart, ... Smart Mart has stated to offer wearable, and customers can find clothing at ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process ... 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , ... wrong, run afoul of The Quality System Regulation (§820.250), and Devicemakers find themselves ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... Eli Lilly and Company (NYSE: LLY ) ... and lasmiditan, two investigational treatments for migraine, at the ... place Sept. 7-10 in Vancouver . ... from an open-label study evaluating the safety and effectiveness ... mg) for the prevention of migraine. Galcanezumab is a ...
(Date:9/5/2017)... Sept. 5, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of oral ... concluded its meeting with the U.S. Food and Drug ... formulation. At the ... pathway for submission of ORMD-0801, would be a Biologics ...
(Date:8/29/2017)... 2017 ivWatch, LLC, the leading provider of continuous monitoring ... has been awarded an Innovative Technology contract from Vizient, Inc., the ... ... in the early detection of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ...
Breaking Medicine Technology: